Non-psychotropic cannabinoids as inhibitors of TET1 protein.

Cannabidiol / chemistry Cannabinoids / pharmacology Cannabinol / pharmacology Cannabis / chemistry Ferrous Compounds Molecular Docking Simulation
Cannabinoids DNA methylation Epigenetic Iron chelation TET1 protein

Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
07 2022
Historique:
received: 20 04 2021
revised: 30 03 2022
accepted: 03 04 2022
pubmed: 25 4 2022
medline: 7 6 2022
entrez: 24 4 2022
Statut: ppublish

Résumé

Non-psychotropic cannabinoids (e.g., cannabidiol, cannabinol and cannabigerol) are contained in numerous alimentary and medicinal products. Therefore, predicting and studying their possible side effects, such as changes in DNA methylation, is an important task for assessing the safety of these products. Interference with TET enzymes by chelating ferrous ions can contribute to the altered methylation pattern. All tested cannabinoids displayed a strong affinity for Fe(II) ions. Cannabidiol and cannabinol exhibited potent inhibitory activities (IC

Identifiants

DOI: 10.1016/j.bioorg.2022.105793 PMID: 35462234
pubmed: 35462234
pii: S0045-2068(22)00198-5
doi: 10.1016/j.bioorg.2022.105793
pii:
doi:

Substances chimiques

Cannabinoids 0
Ferrous Compounds 0
Cannabidiol 19GBJ60SN5
Cannabinol 7UYP6MC9GH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105793

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Veronika Antonyová (V)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic.

Zdeněk Kejík (Z)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic.

Tereza Brogyanyi (T)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic.

Robert Kaplánek (R)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic.

Kateřina Veselá (K)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic.

Nikita Abramenko (N)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic.

Tomáš Ocelka (T)

CannabiLab, GMP Testing and Production Facility, E&H Services, Inc., Dobra 240, 73951, Czech Republic.

Michal Masařík (M)

Department of Physiology and Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 8 CZ-625 00 Brno, Czech Republic.

Adam Matkowski (A)

Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Borowska 211, 50556 Wroclaw, Poland.

Jakub Gburek (J)

Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Borowska 211A, 50556 Wroclaw, Poland.

Renata Abel (R)

Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Borowska 211, 50556 Wroclaw, Poland; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Philippstrasse 12, Berlin, Germany.

Andrean Goede (A)

Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Philippstrasse 12, Berlin, Germany.

Robert Preissner (R)

Science-IT and Institute of Physiology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Philippstrasse 12, 10115, Berlin, Germany.

Petr Novotný (P)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic.

Milan Jakubek (M)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic. Electronic address: milan.jakubek@lf1.cuni.cz.

Articles similaires

Decoding the genomic terrain: functional insights into 14 chemosensory proteins in whitefly Bemisia tabaci Asia II-1.

M N Rudra Gouda, Sabtharishi Subramanian
1.00
Animals Hemiptera Insect Proteins Phylogeny Insecticides

Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization.

Kelly C Young-Wolff, Natalie E Slama, Lyndsay A Avalos et al.
1.00
Humans Female Pregnancy California Adult

Drug repurposing against fucosyltransferase-2 via docking, STD-NMR, and molecular dynamic simulation studies.

Muhammad Atif, Humaira Zafar, Atia-Tul- Wahab et al.
1.00
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans

A head-to-head comparison of MM/PBSA and MM/GBSA in predicting binding affinities for the CB

Mei Qian Yau, Clarence W Y Liew, Jing Hen Toh et al.
1.00
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Cannabinoïdes › Cannabidiol › Non-psychotropic cannabinoids as inhibitors of...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Cannabinoïdes › Non-psychotropic cannabinoids as inhibitors of...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Cannabinoïdes › Cannabinol › Non-psychotropic cannabinoids as inhibitors of...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Rosanae › Rosales › Cannabaceae › Cannabis › Non-psychotropic cannabinoids as inhibitors of...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du fer › Composés du fer II › Non-psychotropic cannabinoids as inhibitors of...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › Non-psychotropic cannabinoids as inhibitors of...